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Abstract
Impaired expression of selenium-containing proteins leads to perturbed thyroid hormone (TH) levels, indicating the central
importance of selenium for TH homeostasis. Moreover, critically ill patients with declining serum selenium develop a
syndrome of low circulating TH and a central downregulation of the hypothalamus-pituitary-thyroid axis. This prompted us
to test the reciprocal effect, i.e., if TH status would also regulate selenoprotein expression and selenium levels. To
investigate the TH dependency of selenium metabolism, we analyzed mice expressing a mutant TH receptor a1 (TRa1+m)
that confers a receptor-mediated hypothyroidism. Serum selenium was reduced in these animals, which was a direct
consequence of the mutant TRa1 and not related to their metabolic alterations. Accordingly, hyperthyroidism, genetically
caused by the inactivation of TRb or by oral TH treatment of adult mice, increased serum selenium levels in TRa1+m and
controls, thus demonstrating a novel and specific role for TRa1 in selenium metabolism. Furthermore, TH affected the mRNA
levels for several enzymes involved in selenoprotein biosynthesis as well as serum selenoprotein P concentrations and the
expression of other antioxidative selenoproteins. Taken together, our results show that TH positively affects the serum
selenium status and regulates the expression of several selenoproteins. This demonstrates that selenium and TH
metabolism are interconnected through a feed-forward regulation, which can in part explain the rapid parallel
downregulation of both systems in critical illness.
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Introduction
Thyroid hormones (THs) are important regulators of develop-
ment and metabolism [1,2]. Their action is mainly exerted by two
nuclear TH receptors (TRs), TRa and TRb, which are potent
regulators of gene transcription in both the presence and absence
of ligands [3]. Circulating TH levels are tightly controlled by the
feedback regulatory system of the hypothalamus-pituitary-thyroid
(HPT) axis [4]. Yet, a number of environmental agents have been
described capable of interfering with HPT axis regulation [5]. In
addition, extreme physiological situations have been shown to
affect the HPT axis and its set points including fasting [6],
neurological diseases [7] and abnormal light-dark cycles [8].
However, one of the most intensively studied perturbations of TH
feedback regulation is found in critically ill patients and has been
described as ‘‘low T3 syndrome’’, ‘‘nonthyroidal illness’’ or
‘‘euthyroid-sick syndrome’’ [9,10]. Here, a central downregulation
of the HPT-axis takes place which is characterized by low TSH
and reduced triiodothyronine (T3) and thyroxine (T4) levels [11].
Interestingly, circulating selenium (Se) concentrations decline in
parallel to the deranged HPT-axis in critical illness [12]. As Se is
required for the 21
st proteinogenic amino acid selenocysteine, it
has been proposed that the impaired expression of selenoproteins
such as the T4 activating 59-deiodinase (Dio) type 1 and 2
isozymes in combination with an induced activity of the TH-
inactivating 5-Dio type 3 underlie the altered serum TH pattern
[11]. Especially in the hypothalamus, a disturbed expression of Se-
dependent Dio might contribute to the aetiology of the syndrome
[13], but the exact molecular alterations have not been fully
clarified [14].
In critically ill patients, both the low serum Se- and low T3-
concentrations represent negative prognostic markers for survival
[15,16]. Unfortunately, Se supplementation trials in such patients
have failed to improve TH metabolism and normalize the
feedback system [17]. We thus hypothesized that the reduced
TH levels are not only the consequence of the low serum levels of
Se, but also contribute causally to the development of the
syndrome. To investigate the role of TH and TRs in the
regulation of Se metabolism, we used mice heterozygous for the
mutant TRa1R384C (TRa1+m mice). The chosen mutation
reduces the affinity of TRa1 to the ligand T3 10-fold, thus
conferring a receptor-mediated hypothyroid state specifically for
TRa1 under otherwise euthyroid conditions [18]. A particular
advantage of the animal model is also that the mutant TRa1 can
be reactivated by supraphysiological doses of TH, either by oral
treatment or endogenously by crossbreeding to hyperthyroid TRb
mice, thus allowing the differentiation between TRa1 and TRb
actions.
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positively regulates serum Se and selenoprotein P (Sepp) levels.
Our results imply a self-amplifying cycle of decreasing TH levels
causing reduced Se availability, which in turn impairs the
activation of T4 by the Se-dependent Dios and the Se dependent
function of the HPT axis.
Methods
Ethics Statement
Animal care procedures were in accordance with the guidelines
set by the European Community Council Directives (86/609/
EEC). Required permissions were obtained from the local ethical
committee (Stockholms Norra Djurfo ¨rso ¨ksetiska Na ¨mnd, No 74/
07).
Experimental Animals
The mouse strain carrying the dominant-negative R384C
mutation in TRa1 has been described previously [18]. The
TRa1+m mice used for the experiments have been backcrossed to
C57BL6/6NCrl for 8–10 generations. In addition, TRa1+m have
been crossed to TRb-deficient mice yielding TRa1+mT R b2/2
double mutants as described in detail previously [19]. If not
indicated otherwise, littermate male mutant and wild-type mice
were born by wild-type females, and 5 animals per group were
used for the experiments at the age of 4–7 months. For certain
experiments, wild-type and TRa1+m mice were exposed to high
levels of maternal TH during embryonal development using
hyperthyroid TRb2/2 mice as dams (19). The animals were
housed at 21C on a 12 h light/12 h dark cycle. For thermo-
neutrality studies, mice were transferred to 30C at the age of 2
months and kept at this temperature for 6 weeks. If required, mice
were treated with T3 via their drinking water containing 0.01%
albumin and 0.5 mg/ml T3 for 12 days. Urine was collected by
putting the animals on the surface of a mirror.
Trace Element Analysis
Serum samples were diluted with ultrapure H2O and a Gallium
standard solution was added as internal control. Tissue samples
were digested in 0.1 M nitric acid for 3 hours at 150C and
supplemented with the Gallium standard. A benchtop total
reflection X-ray fluorescence (TXRF) photometer (Picofox
TM
S2, Bruker, Karlsruhe, Germany) was used to determine Se
concentrations. Samples were applied to glass carriers and
measured as described [20]. Intra assay CV was below 10% for
a human serum reference sample (Sero, Billingstad, Norway),
which was used to control quality of the measurements. Se
analyzes were done in a blinded fashion with respect to the
genotype and T3 treatment of the mice in a remote lab abroad
from the animal facility.
Realtime PCR
RNA was isolated from snap-frozen tissues using the RNeasy
Mini Kit (Qiagen, Solna, Sweden) according to the manufacturer’s
instructions. Subsequent cDNA synthesis of 4 mg of RNA was
carried out using Oligo(dT) Primers and the Transcriptor First
Strand cDNA synthesis Kit (Roche, Stockholm, Sweden).
Quantitative Realtime PCR was performed with the 7300 Real
Time PCR System (Applied Biosystems, Stockholm, Sweden) and
the FastStart Universal SYBR Green PCR Master Mix (Roche,
Stockholm, Sweden). Specificity of amplification was verified by
melting curve analyzes. A standard curve was used to correct for
PCR efficiency and the results were normalized using HPRT as
reference gene. The sequences of the primers used to amplify
selenoprotein and Se-related enzyme transcripts are described
elsewhere [21]; additional details are available on request.
Glutathion Peroxidase (Gpx) Activity Assay
Serum, hepatic and renal Gpx activities were determined at
30C by a NADPH-coupled enzymatic test using tert-BuOOH as
substrate [22] with modifications as described previously [23]. The
activity was normalized against the volume (serum) or protein
content (tissue) of the sample, which was determined using a
commercial protein assay dye (Biorad, Sundbyberg, Sweden).
Western Blot Analysis
Sepp concentrations in murine serum were determined by
Western blot as described recently [24]. Briefly, murine serum
(0.2 ml/lane) was separated in a SDS/10% polyacrylamide gel.
After electrotransfer, the nitrocellulose membrane (Protran,
Schleicher & Schuell, Dassel, Germany) was stained with Ponceau
S (PonS) in order to control complete transfer and equal loading of
the lanes. The membrane was photographed and blocked with 5%
skim milk for 1 h at room temperature. Antibodies against mouse
Sepp have been described previously [25] and were used at 1:400
dilution. Secondary goat anti rabbit antibodies (DAKO, Ham-
burg, Germany) have been used at 1:2000 dilution. Quantification
of the PonS staining and the Western Blot were done by ImageJ,
and the results show the ratio (Western Blot/PonS) normalized to
the wild-type results.
Statistics
Values are presented as means 6 standard error of the mean
(SEM). Statistical significance was calculated by a two-way-
ANOVA followed by a Bonferroni post hoc test and considered
significant if P,0.05 (*), P,0.01 (**), or P,0.001 (***).
Results
To test whether TH signalling affects the Se status in vivo, wild-
type and TRa1+m mutant mice were analyzed. Hyperthyroidism
was induced in a separate group of mice by applying T3 to their
drinking water for 12 days prior to analysis. Total Se was analyzed
in samples from serum, urine, liver and kidneys (Fig. 1A).
Circulating Se concentrations were significantly lower in TRa1+m
mice than in wild-type controls (p,0.01), and T3 increased serum
Se levels by 20% in both genotypes (p,0.001). Urine and liver Se
concentrations were not significantly altered in TRa1+m mice and
not affected by the T3 treatment. In contrast, renal Se
concentrations were significantly increased by T3 treatment. In
summary, these data indicate that Se concentrations are regulated
in kidney and serum in a T3- and TRa1-dependent manner.
TRa1+m mice exhibit a severe hypermetabolism at room
temperature which can be normalized when the animals are
reared at thermoneutrality [26]. To analyze if the increased
metabolism at room temperature is the cause for the reduced
serum Se concentrations observed in the mutant animals, we
compared them with mice housed at 30C (Fig. 1B). The difference
in serum Se concentrations persisted at thermoneutrality (p,0.05
for wild-type vs TRa1+m, p=0.39 for room temperature vs
thermoneutrality), indicating that the differences in serum Se
status are unrelated to the metabolic activity.
As serum Se concentrations are mainly controlled by hepati-
cally-derived Sepp, the Se transport protein accounting for most of
the circulating Se in both rodents and humans [27], we
determined RNA levels for Sepp and other hepatic selenoproteins
and enzymes involved in selenoprotein biosynthesis. We found no
significant difference in any of the mRNA levels when comparing
Selenium in TRa1+m Mice
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agreement with the lesser role of this TH receptor isoform in
the liver [28]. However, a strong effect of T3 treatment was
observed for Gpx1 and Dio1 mRNA in agreement with the
literature [29]. Similarly, T3 also induced the expression of
selenocysteine synthase SecS [30]. In contrast, transcript levels of
phosphoseryl-tRNA kinase (Pstk), a dynamically regulated and
limiting component of the hepatic selenoprotein biosynthesis
machinery [21,31], remained constant upon T3 stimulus, similar
to selenoprotein H (SelH) and selenoprotein W (SelW) mRNA.
Taken together, as hepatic Sepp, Pstk and SecS mRNA expression
were not impaired, the analysis of hepatic gene expression failed to
explain the decreased serum Se concentrations in TRa1+m mice
and its increase upon T3 treatment.
We therefore analyzed gene expression in the kidneys as they
are the major site of Se clearance. Megalin (Lrp2) is known to
serve as a renal Sepp-receptor participating in Sepp binding and
re-uptake from the primary filtrate in the proximal tubules [32].
Surprisingly, megalin mRNA concentrations strongly decreased in
wild-type mice upon T3 treatment, but not in T3-treated
TRa1+m littermates, indicating an important role for intact
TRa1 signalling in the regulation of megalin mRNA expression
(Fig. 2B). In parallel, mRNA levels of Sepp, Gpx1, SelH and SelW
as well as Dio1 were increased in the kidney of T3-treated mutant
and wild-type mice. Except for the strong effects on megalin, the
T3-dependent changes of transcript levels were similar for the
investigated genes in both strains of mice. It remains at present
unclear whether a down-regulation of megalin transcripts by T3
contributes to altered Sepp serum levels and serum Se status in
wild-type mice. As renal megalin mRNA concentrations do not
follow serum Se in T3-treated TRa1+m mice, it is unlikely that
this transporter alone is responsible for the different Se levels in the
two genotypes.
As selenoprotein expression is strongly regulated at the post-
transcriptional level, we also determined enzymatic activity of the
Se-dependent Gpx as a TH target in liver and kidney (Fig. 3A).
While no significant difference was observed in hepatic Gpx
activity between the two genotypes, the renal activity was
increased in TRa1+m mice compared to wild-type littermates.
Upon T3 treatment, the activity of this enzyme decreased in the
liver of both animal models, while in the kidney it was not affected
by the hormone. That the effects observed on Gpx activity were
not in accordance with the changes in the respective transcript
levels supports previous studies demonstrating the tissue-specific
regulation of selenoprotein expression at the posttranscriptional
level [33].
To define the contributions of different serum Se proteins to the
phenotype we analyzed the enzyme activity of Gpx3 in the serum
of wild-type and TRa1+m mice with and without T3 treatment
(Fig. 3B). The activity of Gpx3 was lower in TRa1+m mice, thus it
is likely to contribute to the reduced serum Se in these animals.
However, GPx3 activity was not altered by T3 in either genotype,
Figure 1. Selenium levels in wild-type and TRa1+m mutant
mice with or without T3 treatment. A) Analysis of selenium
concentration in serum, urine, liver and kidney of wild-type mice (wt,
white bars) and animals heterozygous for a mutant TRa1( +m, black
bars), untreated or treated with supraphysiological doses of thyroid
hormone (T3-treated). (##:p ,0.01 for genotype, **: p,0.01 for T3
treatment, ***: p,0.001 for T3 treatment, 2-way ANOVA, n=10 for
serum, n=5 for tissues and urine per group). B) Serum levels of
selenium in wild-type (wt, white bars) and TRa1+m mice (+m, black
bars) at thermoneutrality (30C). (#:p ,0.05 for genotype, p=0.39 for
environmental temperature).
doi:10.1371/journal.pone.0012931.g001
Selenium in TRa1+m Mice
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obvious difference was observed in serum Sepp between wild-type
and TRa1+m mice as analyzed by Western Blot, treatment with
T3 significantly increased the Sepp concentrations in the serum of
both genotypes (Fig. 3B), which corresponds well with the increase
observed in serum Se in these mice.
To investigate whether the different Se levels in TRa1+m mice
were a defect caused by the mutant TRa1 acting during embryonal
development or a direct consequence of the TRa1R384C
aporeceptor activity, we exposed the mutant mice to elevated levels
of TH pre- and postnatally, thus reactivating the mutant receptor
specifically in these periods (18). When the TRa1 signalling was
restored during embryonal development using hyperthyroid
TRb2/2 mice as dams (Fig. 4, ‘‘high maternal TH’’), the
TRa1+m mice still exhibited lower serum Se as adults than wild-
type littermates comparable to the normal situation. However,
when we reactivated the mutant TRa1 postnatally by crossing
TRa1+m mice to TRb deficient animals, which exhibit endoge-
nously high level of TH (19), Se levels were strongly increased in
hyperthyroid TRb2/2 and TRa1+mT R b2/2 double mutant
animals (Fig. 4, ‘‘High Endogenous TH’’). These results clearly
demonstrate that Se levels are regulated by TRa1: in euthyroid
TRa1+m mice, the mutant TRa1 suppresses serum Se due to its
potent aporeceptor activity (comparable to the situation found in
hypothyroidism), whereas high levels of TH (either by oral T3
treatment or genetically by crossbreeding to hyperthyroid TRb2/
2 mice) activate TRa1 and confer an increase in serum Se even in
the absence of TRb.
Discussion
The importance of the Se status for health and disease gains
increasing recognition [34,35,36,37]. Although the definition of an
appropriate Se status is still debated, several biomarkers are
currently in use to assess it [36,38]. Selenoprotein enzymes have
emerged as the central mediators of Se supplementation and
medical Se effects. This notion is well manifested by the
interaction of the family of Se-dependent Dios with TH
Figure 3. Hepatic, renal and serum glutathione-peroxidase
activity and serum Sepp concentrations in wild-type and
TRa1+m mice with or without T3 treatment. A) Enzymatic activity
of glutathione peroxidase (Gpx) in liver and kidney of untreated and TH
treated (T3-treated) wild-type (wt, white bars) and TRa1+m mice (+m,
black bars). The activity is normalized against the protein content of the
sample. (**: p,0.01 for T3 treatment, ##:p ,0.01 for genotype, 2-way
ANOVA, n=5 for each group). B) Enzymatic activity of serum
glutathione peroxidase 3 (Serum Gpx) and concentrations of selenium
protein P (Serum Sepp) levels in serum of untreated and TH treated (T3-
treated) wild-type (wt, white bars) and TRa1+m mice (+m, black bars).
(#:p ,0.05 for genotype, **: p,0.01 for T3 treatment, 2-way ANOVA).
doi:10.1371/journal.pone.0012931.g003
Figure 4. Effects of maternal or postnatal hyperthyroidism on
serum selenium. Serum levels of selenium in wild-type (wt, white
bars) and TRa1+m mutants (+m, black bars) born by hyperthyroid
TRb2/2 mothers (high maternal TH), with inactivation of TRb, which
causes endogenous postnatal hyperthyroidism (high endogenous TH),
or a combination of both (high endogenous, high maternal TH).
(***: p,0.001 for T3 treatment, 2-way ANOVA, n=5 per group).
doi:10.1371/journal.pone.0012931.g004
Figure 2. Hepatic and renal gene expression in wild-type and TRa1+m mice with or without T3 treatment. A) Expression profiling of
genes involved in selenium metabolism in livers of untreated and TH treated (T3-treated) wild-type (wt, white bars) and TRa1+m mice (+m, black
bars). The expression is normalized against the housekeeping gene HPRT. Sepp: selenoprotein P, SecS: selenocysteine t-RNA synthase, Sebp1:
selenium binding protein 1, Pstk: phosphoseryl-tRNA kinase, EFsec: selenocysteine-specific elongation factor, Sephs2: selenophosphate-synthetase 2,
mScLy: selenocysteine lyase, GPx1: glutathione peroxidase 1, Dio1: deiodinase type I, SelW/SelH: selenoprotein W or H. B) Expression profiling of
genes involved in selenium metabolism in kidneys of untreated and TH treated (T3-treated) wild-type (wt, white bars) and TRa1+m mice (+m, black
bars). The expression is normalized against the housekeeping gene HPRT. Dio1: deiodinases type I, Sepp: selenoprotein P, Gpx1: glutathione
peroxidase 1, Gpx3: glutathione peroxidase 3, SelW/SelH: selenoprotein W or H. (###:p ,0.001 for T3 treatment of the wild-type, *: p,0.05 for T3
treatment, **: p,0.01 for T3 treatment, ***: p,0.001 for T3 treatment, 2-way ANOVA with Bonferroni post hoc test, n=5 for each group).
doi:10.1371/journal.pone.0012931.g002
Selenium in TRa1+m Mice
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systems [39,40,41,42]. It has been corroborated in human cross-
sectional analyzes and prospective intervention studies that have
addressed the effects of Se status and Se supplementation on
circulating TH levels [43,44,45]. However, the results are not fully
consistent and even in Se supplementation studies of critically ill
patients with low circulating Se levels and grossly disturbed TH
metabolism, a similar lack of clear effects was reported [17]. Thus,
we hypothesized that serum TH levels might also affect serum Se
levels, i.e. that TH and Se levels are interdependently regulated.
To date the only well-established effect of TH on the
selenoproteome was the regulation of the three Dio isozymes
which are controlled by TH status in liver, kidney, hypothalamus
and pituitary [46,47,48].
Our data provide a novel insight into the interactions of TH and
Se metabolism. The analysis of mice heterozygous for a mutant
TRa1 revealed a reduced serum Se level in these animals. Since
the mutation causes a 10-fold lower affinity to the ligand T3, the
receptor acts as an aporeceptor at physiological TH levels [18] and
tissues expressing the mutant TRa1 exhibit a hypothyroid-like
state specifically for the TRa1 isoform. Taken together with the
fact that serum Se increases upon T3 treatment, our data suggest a
direct regulation of serum Se by TH in a TRa1 dependent
manner. This is supported by the observation that serum Se is also
increased in hyperthyroid TRb2/2mice, which excludes an
involvement of TRb.
Although the precise molecular mechanism remains yet to be
elucidated, our findings provide evidence for a possible model and
for the tissues involved in the regulation. First, it can be concluded
that the increase in serum Se is not due to an altered Se demand of
the thyroid gland, as Se levels are elevated both in T3-treated mice
in which the HPT axis is suppressed and thyroid activity is
reduced, and in TRb2/2 animals, which have endogenously
high levels of TH due to increased thyroid activity.
Secondly, as TRa1 plays only a minor role for the hepatic
mRNA expression of several selenoprotein genes such as Dio1 or
GPx1, which is in line with the literature [29,42,49,50], it seems
unlikely that the transcription of hepatic selenoprotein genes
underlies the difference in selenium metabolism between wild-type
and TRa1+m mutant mice.
In contrast, the kidney seems to be an important target site of
TRa1 action, since we observed a TRa1 dependent regulation of
gene expression in for megalin, an important mediator of renal Se
reuptake [51]. Counterintuitively, however, serum Se levels were
increased in the presence of reduced megalin mRNA expression,
and no increased loss of Se into the urine of T3 treated animals
was observed. This suggests that megalin is not rate-limiting for
efficient renal Sepp reuptake under these conditions or alternative
transporters compensate for its reduction. Alternatively, an
increased renal production of Se- proteins such as GPx could
limit the loss of Se, which is supported by the fact that we indeed
observed increased GPx activity in the kidneys of TRa1+m
mutant mice. This occurs despite unaltered Gpx1 mRNA
concentrations, suggesting a role for TRa1 also in the modulation
of the posttranscriptional biosynthesis of selenoproteins, similar to
the situation found in the sex-specific differences in hepatic
selenoprotein expression [52] or the acute phase effects on liver
selenoprotein biosynthesis [21].
Surprisingly, despite the increased renal GPx activity, serum
GPx activity was decreased in the TRa1+m mutant mice. While
this reduction most likely contributes to the difference in serum Se
levels between the two genotypes, the T3 induction of serum Se
seems to result from an increase of serum Sepp concentrations in
both wild-type and TRa1+m mice. Since the majority of
circulating Sepp is produced by hepatocytes, but hepatic Sepp
mRNA levels remained unaltered upon T3 treatment, it can be
speculated that TH improves the translation of Sepp in the liver.
This could be achieved by an intracellular redistribution of the
available Sec-tRNA away from other selenoproteins towards Sepp;
a hypothesis that is supported by the fact that hepatic GPx activity
declines despite increased GPx mRNA levels and unaltered or
even increased total liver Se concentrations. A similar redistribu-
tion of the available Se for the posttranscriptional control of
selenoprotein production has been reported during acute phase
response, where decreased Sepp production and secretion is
paralleled by increased selenoprotein S biosynthesis in hepatocytes
despite largely unaltered transcript concentrations [24,53]. While
further analyses are required to confirm these molecular pathways,
it can be concluded that TH and TRa1 affect serum Se levels by
specific, yet distinct mechanisms involving hepatic and renal Sepp
and GPx translation.
A limitation of the current study is however the role of TRa1i n
other tissues regulating Se metabolism such as the gastrointestinal
tract [54,55]. This is caused in part by our current limitation of in-
depth knowledge of this process in general and a respective lack of
adequate tools and prime candidates suited to reliably reflect
alterations of gastrointestinal Se uptake. Moreover, TH receptors
can regulate gene expression as heterodimers with e.g. retinoic X
Figure 5. Schematic illustration of the feed-forward reaction
which might take place during critical illness. Declining serum
selenium concentrations cause impaired selenoprotein expression in
the tissues. In parallel, impaired deiodinase expression leads to low T3
concentrations. Both pathways might aggravate each other if the
declining selenium and T3 concentrations are not compensated for by a
combined supplementation effort aiming to meet the patient’s Se and
TH requirements.
doi:10.1371/journal.pone.0012931.g005
Selenium in TRa1+m Mice
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peripheral signals that have not been studied yet.
Nevertheless, the identified changes of serum Se, Sepp content,
and GPx activity in TRa1+m mice are of clinical relevance.
Although several patient families have been identified to date
carrying a mutant TRb and displaying resistance to thyroid
hormone (RTH), none with a mutant TRa1 was found [56,57].
The most likely explanation is given by the notion that the TH
levels in these patients are predicted to be normal and they are
thus not easily associated with a defect in TH signalling [57]. As
these patients would certainly benefit from a correct diagnosis and
treatment, a reliable serum parameter could facilitate their
identification. Given our findings in TRa1+m mice, patients
harbouring a similar mutation would exhibit decreased serum Se
concentrations. As the effects have been of moderate size under
normal conditions only, and mouse lines with distinct mutations in
their TRa1 genes exhibit variable or sometimes even opposite
phenotypic features [18,58,59,60], it remains to be elucidated
whether the reduced serum Se concentrations are solid screening
parameters for identifying subjects with mutant TRa1 genes.
Even more relevant, our data demonstrate that serum T3
positively correlates with serum Se and that an unliganded TRa1,
as in hypothyroidism, reduces serum Se levels. This interconnect-
ed feed-forward regulation of TH and Se may be of paramount
pathophysiological importance in the clinics, and could contribute
to the vicious cycle observed in critical illness in which both
parameters are known to decline in parallel (Fig. 5). At present,
rescue treatments using TH supplements have yielded controver-
sial results in critical illness [61,62,63,64]. Similarly, Se supple-
mentation trials did not provide uniform results. Even though no
trial showed adverse effects of Se, the majority of studies have been
rather small and yielded either null or positive results [65]. Data
from a recently completed multicentre double-blind prospective
trial were explicitly positive [66], especially for the male patients
enrolled [67]. Still, an intensive discussion is currently held about
the best Se dosage regimen, supplement and application modus
[68,69]. Given our findings and the conflicting results for TH and
Se correction trials in critically ill patients, it might be
advantageous to correct T3 status and Se deficiency in parallel
to interrupt the self-amplifying pathogenic mechanism aggravating
the disease and all too often causing a deadly outcome (Fig. 5).
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